Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mouthwash regimens to prevent ventilator-associated pneumonia
IRCT20200825048515N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of colistin, tobramycin and chlorhexidine in ventilator-associated pneumonia (VAP) (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Incidence of ventilator-associated pneumonia. Started Sep 2020; status: completed.
02
Drugs
colistintobramycinchlorhexidine
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on IRCT20200825048515N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N1.